Wedbush Maintains Underperform on Praxis Precision Medicine, Raises Price Target to $166

Benzinga Newsdesk www.benzinga.com Positive 63.0%

Neg 0% Neu 0% Pos 63%

Wedbush analyst Laura Chico maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Underperform and raises the price target from $130 to $166.